Rosehip

Metadata

Approved Indications

Commission E (Germany)

• Negative monograph: Commission E published a negative assessment for Rosa canina pseudo-fruit (Rosae pseudo-fructus cum fructibus), citing insufficient evidence of efficacy at the time of review
• The Commission E monograph that exists is for the pseudo-fruit as a source of vitamin C and as a mild laxative (due to fruit acid content), not for the musculoskeletal indication

ESCOP

• Osteoarthritis: ESCOP has published a monograph supporting the use of rosehip powder for symptomatic relief of osteoarthritis
• The indication is based on the clinical trial evidence from the Warholm, Rein, and Winther studies

EMA/HMPC (European Medicines Agency)

• Status: Traditional Use
• Indications:
  • Traditional herbal medicinal product used as a supplementary source of vitamin C
  • Traditional herbal medicinal product for the relief of minor joint pain (articular pain)
• Monograph Reference: EMA/HMPC/159076/2014 (Rosa canina L., pseudo-fructus)
• Note: The EMA traditional use monograph is based on long-standing use rather than on the clinical trial evidence for OA; the agency has not granted well-established use status

Agreement/Disagreement Between Bodies

• Disagreement: Commission E (negative) vs ESCOP (positive for OA) reflects the evolution of evidence over time — the Commission E review predated the key clinical trials
• EMA position: The EMA acknowledges traditional use for minor joint pain but has not evaluated the OA clinical evidence to the level required for well-established use
• Practical significance: The ESCOP monograph provides the strongest regulatory support for the musculoskeletal indication

Conditions Treated

Primary (Moderate Evidence)

• Osteoarthritis (knee and hip): Symptomatic pain relief and improved mobility, supported by a meta-analysis of 3 RCTs (ES 0.37, NNT 6); most consistent evidence for knee OA

Secondary (Limited Evidence)

• Rheumatoid arthritis: One open-label study showed reduced CRP and improved antioxidant status; insufficient evidence for clinical recommendation
• General joint stiffness and pain: Traditional use as anti-inflammatory; some support from the OA trial data

Traditional/Historical (Insufficient Clinical Evidence)

• Vitamin C supplementation (historically used to prevent scurvy)
• Mild laxative effect (due to fruit acids in the hip)
• Immune support and common cold prevention (traditional vitamin C indication)
• Kidney and urinary tract conditions (traditional European use)

Mechanism of Action

Primary Mechanisms

Anti-inflammatory (galactolipid-mediated):

• The galactolipid GOPO has been identified as a primary active constituent through bioassay-guided fractionation
• GOPO inhibits chemotaxis of peripheral blood polymorphonuclear leukocytes (neutrophils) and monocytes in vitro, reducing inflammatory cell migration to joint tissue
• This mechanism is distinct from the COX/LOX inhibition typical of most herbal anti-inflammatories (e.g., devil’s claw, willow bark)
• GOPO also inhibits the expression of inflammatory mediators in cartilage cell cultures

Antioxidant:

• High content of ascorbic acid, carotenoids (lycopene, beta-carotene), and polyphenols provides broad-spectrum antioxidant activity
• Reduced oxidative stress markers have been demonstrated in clinical studies (Willich et al. 2010)
• Antioxidant activity may protect cartilage from oxidative degradation

Secondary Mechanisms

Distinguishing Feature

• Unlike most herbal anti-inflammatories that work primarily through COX/LOX inhibition, rosehip appears to act primarily through inhibition of leukocyte chemotaxis, representing a mechanistically distinct approach to joint inflammation

Clinical Evidence Summary

Volume of Evidence

• Small but consistent. Three RCTs with a total of approximately 300 patients, plus one meta-analysis. All key trials used the same proprietary product (Hyben Vital/LitoZin) and were industry-sponsored.

Key Studies

Osteoarthritis

Other Conditions

Evidence Gaps

• No independent replication outside industry-sponsored trials
• No large-scale (>200 patients per arm) trials
• No head-to-head comparisons with standard NSAIDs or other herbal anti-inflammatories
• No long-term studies (>6 months)
• No dose-response studies
• Limited data on mechanism of action in vivo
• Unclear whether benefits are specific to the LitoZin subtype of Rosa canina or generalizable to all rosehip preparations

European vs US/Anglophone Consensus

Safety Profile

Contraindications

• Known hypersensitivity to Rosa canina or other Rosaceae plants
• No absolute contraindications are established at standard doses

Drug Interactions

• No clinically significant drug interactions have been documented
• Theoretical concern: High vitamin C content could theoretically affect iron absorption or interact with anticoagulants, but this has not been observed in clinical studies at standard rosehip powder doses (5 g/day)
• No CYP enzyme interactions have been reported

Side Effects

• Generally very well tolerated in clinical trials
• Mild gastrointestinal discomfort (nausea, diarrhea, constipation) reported occasionally in trials, at rates similar to placebo
• Allergic reactions are rare but possible in individuals allergic to roses or other Rosaceae family plants

Pregnancy/Lactation

• Pregnancy: Insufficient data; traditional use as a vitamin C source during pregnancy exists, but medicinal doses for OA have not been evaluated in pregnant women. Use in pregnancy should be supervised by a healthcare provider
• Lactation: Insufficient data; rosehip as a food/tea is considered safe, but therapeutic doses are not specifically evaluated
• Children: Not specifically studied for the OA indication; traditional use as a vitamin C source in children is common

Clinical Dosage

Standard Dosage Forms

Key Dosing Notes

• OA indication: All clinical evidence is based on 5 g/day of standardized rosehip powder (Hyben Vital/LitoZin product), taken as 2.5 g twice daily with food
• Onset of action: Clinical trials suggest 3-4 weeks before noticeable benefit; full effect at 3 months
• Duration: Studied for up to 4 months; long-term use data is lacking but no safety signals have been identified
• Equivalence uncertainty: It is not established whether generic rosehip powders are equivalent to the specific LitoZin subtype used in trials

EMA/HMPC Recommended Doses

• Herbal tea: 1-5 g of cut or powdered hip in 150 mL boiling water, 2-3 times daily
• Duration: If symptoms persist beyond 2 weeks, a physician should be consulted

Sources

• Christensen R, et al. Does the hip powder of Rosa canina (rosehip) reduce pain in osteoarthritis patients? — a meta-analysis of randomized controlled trials. Osteoarthritis Cartilage. 2008;16(9):965-972
• Winther K, et al. A powder made from seeds and shells of a rose-hip subspecies (Rosa canina) reduces symptoms of knee and hip osteoarthritis: a randomized, double-blind, placebo-controlled clinical trial. Scand J Rheumatol. 2005;34(4):302-308
• Rein E, et al. A herbal remedy, Hyben Vital (stand. powder of a subspecies of Rosa canina fruits), reduces pain and improves general wellbeing in patients with osteoarthritis — a double-blind, placebo-controlled, randomised trial. Phytomedicine. 2004;11(5):383-391
• Warholm O, et al. The effects of a standardized herbal remedy made from a subtype of Rosa canina in patients with osteoarthritis: a double-blind, randomized, placebo-controlled clinical trial. Curr Ther Res. 2003;64(1):21-31
• Willich SN, et al. Rose hip herbal remedy in patients with rheumatoid arthritis — a randomised controlled trial. Phytomedicine. 2010;17(2):87-93
• Schwager J, et al. Rose hip and its constituent galactolipids confer cartilage protection by modulating cytokine and chemokine expression. BMC Complement Altern Med. 2011;11:105
• Kharazmi A. Laboratory and preclinical studies on the anti-inflammatory and anti-oxidant properties of rosehip powder — identification and characterization of the active component GOPO. Osteoarthritis Cartilage. 2008;16(Suppl 1):S5-S7
• EMA/HMPC Community Herbal Monograph on Rosa canina L., pseudo-fructus (EMA/HMPC/159076/2014)
• ESCOP Monograph: Rosae pseudo-fructus (Rose hip)
• Gruenwald J, et al. Rosa canina — Rose hip pharmacological ingredients and molecular mechanics counteracting osteoarthritis — a systematic review. Phytomedicine. 2019;60:152958

Connections

• Compare with Devil’s Claw as a fellow musculoskeletal herb; devil’s claw has a much larger evidence base and works through a different mechanism (iridoid glycoside harpagoside vs galactolipid GOPO)
• Compare with Boswellia as another herbal anti-inflammatory for OA; boswellia acts via 5-LOX inhibition, while rosehip acts primarily through leukocyte chemotaxis inhibition
• Related to Willow Bark as a traditional European remedy for joint pain; willow bark has salicin-based COX inhibition, providing a mechanistically complementary approach
• Compare with Turmeric/Curcumin as a widely studied anti-inflammatory supplement for OA; curcumin has a larger evidence base but bioavailability challenges that rosehip powder does not share